한국어
Quantus

M.I.TECH

179290 · KOSDAQ
₩5,100-0.78%
2026-09-04 close

M.I.TECH last closed at ₩5,100 (-0.78%) on 2026-09-04. Signals today: VCP. Listed on KOSDAQ; price, financials and dividends update daily after market close.

Loading chart…
Close
No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p

Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.

Trade plan

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

A+
Overall: 건강관리 13/291 · top 4%
Factor composite · relative position in sector

PER 9.03 · PBR 1.52 — own-history percentile 100/100 · 100/100

Open self-history band
PER100/100
PBR100/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Annual dividend

Split-adjusted annual DPS history and available grade axes

Annual dividend per share chart2019: 50원20192020: 50원2021: 60원2022: 80원2023: 120원2024: 80원2025: 100원100원2025
Annual dividend (per share · split-adjusted) · as of 2025
Consistency
B-
Growth
B+
Yield
B-
Safety
A-
Reference indicatorView observed cut rates

Paid 7 consecutive years · Raised 1 consecutive years · Yield 1.96% (based on 2025 payment of 100원) · 3-year growth +7.7%

Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.

Financial safety

Reference indicatorAs of 2024
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 18.98
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
18.98
Beneish M-Score
-3.00

No statistical flag

Sloan accrual
-4.53%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Why has this company moved this way?

Auditable observations with the original numeric evidence.

매출 성장 + 마진 확대 + FCF 양수

Positive

매출이 +15.9% 성장하면서 영업이익률이 30.3%에서 32.7%로 확대되었다. FCF도 양수를 유지하여 질적 성장이 확인된다.

Evidence

매출 YoY +15.9%영업이익률 30.3%→32.7%FCF 24,823

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

6/9Moderate

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score6/9

Profitability

  • Positive ROAPass
  • Positive OCFPass
  • Improving ΔROAPass
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesPass

Efficiency

  • Higher gross marginPass
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Industry structure

KRAs of 2026-09-05

건강관리

This stock is in 건강관리: revenue rank 166 of 287, share 0.1%.

166 / 2870.1%revenue share

Who dominates this industry?

  1. 1삼성바이오로직스7.3%
  2. 2셀트리온5.7%
  3. 3녹십자홀딩스3.5%
  4. 4유한양행3.3%
  5. 5대웅3.1%
  6. 6엠아이텍0.1%

Concentration

DistributedCR3 16.6%
HHI 202287 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
31.61
Direction
확대
Level
넓음
Years
7

Value lens

P90/P10
13.9
Median P/B
1.47
Level
넓음
n
263

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
32.7%
Interest coverage
417.2x
Return on equity (ROE)
16.8%

Operating margin −5pp

Tolerable
Interest coverageBase 417.2x adverse case 353.4x
Return on equity (ROE)Base 16.8% adverse case 13.6%

Revenue −15%

Tolerable
Interest coverageBase 417.2x adverse case 354.6x
Return on equity (ROE)Base 16.8% adverse case 13.7%

Interest rate +2pp

Tolerable
Interest coverageBase 417.2x adverse case 74.5x
Return on equity (ROE)Base 16.8% adverse case 15.9%

Interest coverage limit

Current margin 32.6pp

Interest coverage limit at an operating margin of 0.1%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-03-18

Suppliers disclosed by the company in its 2026-03-18 annual report.

Purchase amount

KRW 100m
  1. WIRE
    KRW 598.1T

Suppliers without disclosed amount

OUTERSHEATHNitinol

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

  • 시너지이노베이션53.09%2026-04-02 · 증감 -0.15%p

Other stocks held by the same investors

A filing-based shared-holder record, not investment advice.

Connections

AI-extracted related companies · for reference

Suppliers
쿡메디컬
🔗 See in the full market map →

Recent filings

M.I.TECH's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

About M.I.TECH
What technical signals does M.I.TECH (179290) have?
M.I.TECH current technical signals: no active technical signal.
Is M.I.TECH a cup-and-handle pattern?
No. M.I.TECH has no valid cup-and-handle signal right now.
What are M.I.TECH's financials and valuation?
M.I.TECH's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy